A5021887374- Cutaneous Melanoma Detection and Management
- Biochemical and Molecular Research
- Cutaneous lymphoproliferative disorders research
- Epigenetics and DNA Methylation
- Autophagy in Disease and Therapy
- Optical Coherence Tomography Applications
- Diversity and Career in Medicine
- Nonmelanoma Skin Cancer Studies
- Autoimmune Bullous Skin Diseases
- Skin Diseases and Diabetes
- Innovations in Medical Education
- Autoimmune and Inflammatory Disorders
- Oral Health Pathology and Treatment
- Medical Education and Admissions
- Vascular Tumors and Angiosarcomas
- Genetic and rare skin diseases.
- Systemic Lupus Erythematosus Research
- Disaster Response and Management
- Dermatological and Skeletal Disorders
- melanin and skin pigmentation
- Genital Health and Disease
- Drug-Induced Ocular Toxicity
- AI in cancer detection
- Sympathectomy and Hyperhidrosis Treatments
- Urological Disorders and Treatments
Alfred Health
2023-2024
Monash University
2020-2024
The Alfred Hospital
2020-2024
The University of Melbourne
2024
Skin Health Institute
2024
Monash Health
2019-2023
Barwon Health
2023
Australian Regenerative Medicine Institute
2021
Gosford Hospital
2020
Wollongong Hospital
2020
Abstract High‐resolution ultrasound (HRUS), operating at frequencies of 20–25 MHz, is a non‐invasive imaging tool that offers dermatologists the ability to visualize structures beneath skin surface. The objective this review present comprehensive overview HRUS applications, emphasising its utility in diagnosing, characterising and managing various dermatological conditions. We undertook literature on application across Medline, Embase Cochrane Library databases, while also incorporating our...
Abstract Objectives It is common practice to advise people with vulvar lichen sclerosus perform self-examination (VSE) optimize topical therapy and detect changes that may represent active disease, scarring, and/or squamous cell carcinoma development. The aim of this study was better understand people's willingness potential barriers performing VSE. Materials Method A cross-sectional survey undertaken all patients LS presenting a tertiary referral dermatology clinic in Australia, from June...
Abstract In this paper, we explore the ethics of restricting visitation to hospitals during an infectious disease outbreak. We aim answer three questions: What are features ethically justified hospital visitor restriction policy? Should policies include scope for case‐by‐case exemptions? How should decisions about exemptions be made? Based on a critical interpretive review existing ethical literature restrictions, argue that policy has following features: proportionality, comprehensiveness,...
To assess specialisation interests in commencing interns and create a standardised survey to aid medical schools, supervisors health services quantifying, understanding supporting career development improve workforce planning.
Abstract The biological and molecular mechanisms that underpin the malignant transformation of normal melanocytes to melanomas are largely unknown. In part, this is due limited understanding human melanocyte homeostasis how respond oncogenic insults such as ultraviolet radiation (UVR). This particularly true for interfollicular epidermal melanocytes, which have highest levels UVR exposure from whence most thought arise. These knowledge gaps impede development strategies active, targeted...
ABSTRACT The enhancer of zeste homolog 2 (EZH2) oncoprotein is a histone methyltransferase that functions canonically as catalytic subunit the polycomb repressive complex (PRC2) to tri-methylate H3 at Lys 27 (H3K27me3). Although targeting EZH2 promising therapeutic strategy against cancer, methyltransferase-independent oncogenic are described. Moreover, pharmacological inhibition was only variably effective in pre-clinical and clinical studies, suggesting alone may be insufficient. Here, we...
The enhancer of zeste homolog 2 (EZH2) oncoprotein is a histone methyltransferase that functions canonically as catalytic subunit the polycomb repressive complex (PRC2) to tri-methylate H3 at Lys 27 (H3K27me3). Although targeting EZH2 promising therapeutic strategy against cancer, methyltransferase-independent oncogenic are described. Moreover, pharmacological inhibition was only variably effective in pre-clinical and clinical studies, suggesting alone may be insufficient. Here, we...
Abstract The enhancer of zeste homolog 2 (EZH2) oncogene is a histone methyltransferase that functions canonically as catalytic subunit the polycomb repressive complex (PRC2) to tri-methylate H3 at Lys 27 (H3K27me3). Although targeting EZH2 promising therapeutic strategy against cancer, methyltransferase-independent oncogenic are also described. Moreover, pharmacological inhibition was only variably effective in pre-clinical and clinical studies, suggesting alone may be insufficient. Here,...